ZLAB – Zai Lab Limited
Zai Lab LimitedZLAB
$35.11Name : Zai Lab Limited
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,916,629,760.00
EPSttm : -2.5
Zai Lab Limited
$35.11
1.05%$0.365Float Short %
4.02
Margin Of Safety %
Put/Call OI Ratio
0.86
EPS Next Q Diff
0.14
EPS Last/This Y
EPS This/Next Y
1.45
Price
34.74
Target Price
52.18
Analyst Recom
1.38
Performance Q
-3.98
Relative Volume
0.62
Beta
0.99
Ticker: ZLAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ZLAB | 31.18 | 0.60 | 0.09 | 5830 |
| 2025-06-03 | ZLAB | 31.14 | 0.60 | 0.60 | 5807 |
| 2025-06-04 | ZLAB | 36.07 | 0.60 | 0.17 | 5818 |
| 2025-06-05 | ZLAB | 36.53 | 0.60 | 0.14 | 5921 |
| 2025-06-06 | ZLAB | 38.11 | 0.58 | 0.04 | 6063 |
| 2025-06-09 | ZLAB | 37.87 | 0.60 | 0.21 | 5925 |
| 2025-06-10 | ZLAB | 40.02 | 0.60 | 0.05 | 5955 |
| 2025-06-11 | ZLAB | 41.4 | 0.59 | 0.38 | 6035 |
| 2025-06-12 | ZLAB | 43.03 | 0.56 | 0.08 | 6157 |
| 2025-06-13 | ZLAB | 40.98 | 0.56 | 0.23 | 6200 |
| 2025-06-16 | ZLAB | 40.57 | 0.56 | 8.00 | 6216 |
| 2025-06-17 | ZLAB | 37.21 | 0.56 | 0.21 | 6219 |
| 2025-06-18 | ZLAB | 36.91 | 0.56 | 0.07 | 6245 |
| 2025-06-20 | ZLAB | 34.43 | 0.56 | 0.16 | 6241 |
| 2025-06-23 | ZLAB | 36 | 0.85 | 0.08 | 4589 |
| 2025-06-24 | ZLAB | 37.58 | 0.84 | 6.00 | 4615 |
| 2025-06-25 | ZLAB | 36.97 | 0.87 | 0.33 | 4678 |
| 2025-06-26 | ZLAB | 36.18 | 0.86 | 0.19 | 4695 |
| 2025-06-27 | ZLAB | 34.8 | 0.86 | 4.00 | 4703 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ZLAB | 31.21 | 49.0 | - | -1.43 |
| 2025-06-03 | ZLAB | 31.13 | 49.0 | - | -1.43 |
| 2025-06-04 | ZLAB | 36.07 | 49.0 | - | -1.43 |
| 2025-06-05 | ZLAB | 36.54 | 49.0 | - | -1.43 |
| 2025-06-06 | ZLAB | 38.09 | 49.0 | - | -1.43 |
| 2025-06-09 | ZLAB | 37.87 | 49.0 | - | -1.43 |
| 2025-06-10 | ZLAB | 40.02 | 49.0 | - | -1.43 |
| 2025-06-11 | ZLAB | 41.38 | 49.0 | - | -1.43 |
| 2025-06-12 | ZLAB | 43.03 | 49.0 | - | -1.43 |
| 2025-06-13 | ZLAB | 41.01 | 49.0 | - | -1.41 |
| 2025-06-16 | ZLAB | 40.57 | 49.0 | - | -1.41 |
| 2025-06-17 | ZLAB | 37.19 | 49.0 | - | -1.41 |
| 2025-06-18 | ZLAB | 36.93 | 49.0 | - | -1.41 |
| 2025-06-20 | ZLAB | 34.55 | 49.0 | - | -1.41 |
| 2025-06-23 | ZLAB | 35.98 | 49.0 | - | -1.41 |
| 2025-06-24 | ZLAB | 37.60 | 48.4 | - | -1.42 |
| 2025-06-25 | ZLAB | 36.97 | 48.4 | - | -1.42 |
| 2025-06-26 | ZLAB | 36.18 | 48.4 | - | -1.42 |
| 2025-06-27 | ZLAB | 34.74 | 48.4 | - | -1.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ZLAB | -22.38 | 5.25 | 4.59 |
| 2025-06-03 | ZLAB | -22.38 | 5.25 | 4.59 |
| 2025-06-04 | ZLAB | -22.78 | 5.25 | 4.59 |
| 2025-06-05 | ZLAB | -22.78 | 5.25 | 4.59 |
| 2025-06-06 | ZLAB | -22.78 | 5.25 | 4.59 |
| 2025-06-09 | ZLAB | -22.78 | 6.38 | 4.59 |
| 2025-06-10 | ZLAB | -22.78 | 6.38 | 4.59 |
| 2025-06-11 | ZLAB | -22.78 | 6.38 | 4.71 |
| 2025-06-12 | ZLAB | -22.78 | 6.38 | 4.71 |
| 2025-06-13 | ZLAB | -22.78 | 6.38 | 4.71 |
| 2025-06-16 | ZLAB | -22.78 | -4.49 | 4.71 |
| 2025-06-17 | ZLAB | -22.78 | -4.49 | 4.71 |
| 2025-06-18 | ZLAB | -22.78 | -4.49 | 4.71 |
| 2025-06-20 | ZLAB | -22.78 | -4.49 | 4.71 |
| 2025-06-23 | ZLAB | -23.35 | -5.65 | 4.68 |
| 2025-06-24 | ZLAB | -23.23 | -5.65 | 4.68 |
| 2025-06-25 | ZLAB | -23.23 | -5.65 | 4.68 |
| 2025-06-26 | ZLAB | -23.23 | -5.65 | 4.02 |
| 2025-06-27 | ZLAB | -24.52 | -5.65 | 4.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.45
Avg. EPS Est. Current Quarter
-0.42
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-24.52
Institutional Transactions
-5.65
Beta
0.99
Average Sales Estimate Current Quarter
126
Average Sales Estimate Next Quarter
153
Fair Value
Quality Score
Growth Score
25
Sentiment Score
73
Actual DrawDown %
82.1
Max Drawdown 5-Year %
-92.8
Target Price
52.18
P/E
Forward P/E
81.4
PEG
P/S
9.18
P/B
4.65
P/Free Cash Flow
EPS
-2.5
Average EPS Est. Cur. Y
-1.42
EPS Next Y. (Est.)
0.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-60.26
Relative Volume
0.62
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Zai Lab LimitedSector: Healthcare
Industry: Biotechnology
Employees: 1869
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is based in Shanghai, China.
stock quote shares ZLAB – Zai Lab Limited Stock Price stock today
news today ZLAB – Zai Lab Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch ZLAB – Zai Lab Limited yahoo finance google finance
stock history ZLAB – Zai Lab Limited invest stock market
stock prices ZLAB premarket after hours
ticker ZLAB fair value insiders trading